Background Dietary sodium restriction remains guidelines-approved lifestyle recommendation for chronic heart failure (CHF) patients. However, its efficacy in clinical outcome improvement is dubious. Methods We performed a systematic review of the following databases: Academic Search Ultimate, ERIC, Health ...
Unphysiologically high intakes of sodium as table salt may increase the blood pressure. A general recommendation based on an overall evaluation of available data states that Na intake in adults should not exceed 2.4 g/day, which corresponds to a limit of about 6 g/day of table salt (...
“Our findings showed that restricting dietary sodium to less than the usual recommendation was counterproductive in the management of heart failure,” said Anirudh Palicherla, MD, an internal medicine resident at Creighton University School of Medicine in Omaha, Nebraska, and the study’s lead auth...
Sodium acid phosphate may be administered orally as solutions or tablets prior to colonoscopy, or rectally as an enema for short-term treatment ofconstipation. Sodium acid phosphate may also be administered as part of intravenous (IV) fluids for parenteralnutritionor to supplement phosphate in patient...
69 The latest guidelines from the European Society of Cardiology also include the same recommendation for the use SGLT2 inhibitors in patients with HFrEF (Class I recommendation).66 Following the DELIVER trial and subsequent meta-analysis of 5 randomized clinical trials of SGLT2 inhibitors in HF, ...
although there is general agreement that sodium reduction is appropriate for persons with hypertension, there are some questions about applying this recommendation to the remainder of the population. part of the hesitation appears to be based on reports of metabolic disturbance, inconsistency in the ...
Evidence is insufficient to make a recommendation for diastolic failure, and lower doses of furosemide might require different dietary advice.doi:10.1097/01.EBP.0000541201.60548.97Ali, NadarAdam, PatriciaEvidence-Based Practice
In the STRONG-HF study, SGLT2is were not included because the start of the trial was prior to the recommendation of these drugs. Subsequently, the EMPULSE trial [18] was published, in which empagliflozin was started between one and five days after hospitalization for AHF, achieving significant...